Gilead Sciences Stock Investor Sentiment

GILD Stock  USD 89.76  1.13  1.27%   
About 57% of Gilead Sciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Gilead Sciences suggests that many traders are alarmed. The current market sentiment, together with Gilead Sciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Gilead Sciences stock news signals to limit their universe of possible portfolio assets.

Panic Vs Confidence

43

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Gilead Sciences' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Gilead Sciences.

Gilead Historical Sentiment

Although Gilead Sciences' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Gilead, such as negative comments on social media and news outlets, may cause fear in the market and push Gilead Sciences' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Gilead.
  

Gilead Sciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Gilead Sciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Gilead Sciences Historical Investor Sentiment

Investor biases related to Gilead Sciences' public news can be used to forecast risks associated with an investment in Gilead. The trend in average sentiment can be used to explain how an investor holding Gilead can time the market purely based on public headlines and social activities around Gilead Sciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Gilead Sciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Gilead Sciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Gilead Sciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Gilead Sciences.
over a week ago at thelincolnianonline.com         
Montecito Bank Trust Sells 1,033 Shares of Gilead Sciences, Inc.
news
over a week ago at stockgumshoe.com         
Small Cap AI bought by Gates Ely Lily, Nvidia End of Disease?
news
over a week ago at businesswire.com         
Gilead Sciences to Present at Upcoming Investor Engagements
businesswire News
over a week ago at thelincolnianonline.com         
Piper Sandler Raises Gilead Sciences Price Target to 105.00
news
over two weeks ago at marketbeat.com         
Gileads Stock Surge Whats Fueling the Momentum?
Marketbeat News
over two weeks ago at fool.com         
Gilead Sciences Tops Estimates in Q3
fool News
over two weeks ago at finance.yahoo.com         
Gilead increases 2024 outlook, expects new drug filing by end of year
Yahoo News
over two weeks ago at investing.com         
Gilead Sciences chief commercial officer sells 456,400 in stock
Investing News at Macroaxis
over two weeks ago at thelincolnianonline.com         
Gilead Sciences Price Target Raised to 105.00 at Piper Sandler
news
over two weeks ago at finance.yahoo.com         
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On...
Yahoo News
over two weeks ago at investing.com         
Gilead Sciences chief medical officer sells 2.34 million in stock
Investing News at Macroaxis
over two weeks ago at seekingalpha.com         
Gilead Sciences in charts Revenue from major products rises YY in Q3
seekingalpha News
over two weeks ago at zacks.com         
Disposition of 5000 shares by Parsey Merdad of Gilead Sciences at 91.5 subject to Rule 16b-3
zacks News
over two weeks ago at zacks.com         
Gilead Reports Q3 Earnings What Key Metrics Have to Say
zacks News
over two weeks ago at seekingalpha.com         
Gilead rises as it raises 2024 sales, non-GAAP EPS outlook
seekingalpha News
Far too much social signal, news, headlines, and media speculation about Gilead Sciences that are available to investors today. That information is available publicly through Gilead media outlets and privately through word of mouth or via Gilead internal channels. However, regardless of the origin, that massive amount of Gilead data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Gilead Sciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Gilead Sciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Gilead Sciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Gilead Sciences alpha.

Gilead Sciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  
 
Gilead Sciences dividend paid on 27th of September 2024
09/27/2024
1
Is Gilead Sciences, Inc. the Best Pharma Stock to Buy Right Now
11/04/2024
2
Gilead Sciences, Inc. Q3 2024 Earnings Call Transcript
11/08/2024
3
Victory Capital Management Inc. Sells 468,814 Shares of Gilead Sciences, Inc.
11/12/2024
4
Decoding Gilead Sciences Inc A Strategic SWOT Insight
11/13/2024
5
Gilead Sciences, Inc. Shares Sold by Bell Bank
11/14/2024
6
Gileads Livdelzi Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
11/15/2024
7
Gilead Sciences shares target upgraded, holds rating on HIV event outlook
11/18/2024
8
TOUCH, The Black Breast Cancer Alliance and Partners Launch the Black TNBC Sanctuary Resource Hub
11/19/2024
9
Cypress Capital Group Reduces Holdings in Gilead Sciences, Inc.
11/21/2024

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital